Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
01 3월 2021 - 10:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of March 2021
Commission File Number 001-34566
China Biologic Products Holdings, Inc.
(Exact name of registrant as specified
in its charter)
18th Floor, Jialong International Building,
19 Chaoyang Park Road
Chaoyang District, Beijing 100125
People’s Republic of China
(+86) 10-6598-3111
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x
Form 40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1)
only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7)
only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which
the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been
the subject of a Form 6-K submission or other Commission filing on EDGAR.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
|
Date:
|
March 1, 2021
|
|
By:
|
/s/ Joseph Chow
|
|
|
|
|
Name:
|
Joseph Chow
|
|
|
|
|
Title:
|
Chairman of the Board of Directors
|
EXHIBIT INDEX
Exhibit
Number
|
|
Description
|
99.1
|
|
Press release dated March 1, 2021 titled “China Biologic Announces Shareholders’ Approval of Merger Agreement”
|
China Bioligic Products (NASDAQ:CBPO)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
China Bioligic Products (NASDAQ:CBPO)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025